Arieh Shalhav
· MD, Professor of SurgeryUniversity of Chicago · Urology
Active 1990–2026
About
Arieh L. Shalhav, MD, is the Fritz and Mary Lee Duda Family Professor of Surgery and serves as the Chief of the Section of Urology at UChicago Medicine. He is a pioneer in minimally invasive laparoscopic and robotic urologic surgery, with extensive experience in laparoscopic kidney surgery and prostate cancer surgery utilizing the Da Vinci Surgical System. Dr. Shalhav was the first urologic surgeon in the region to employ this advanced robotic technique for prostate cancer treatment. His research has significantly contributed to understanding the effects of renal ischemia—oxygen deficiency in the kidney—and developing methods to prevent related damage during surgery. He collaborates with researchers from Argonne National Laboratories to develop innovative techniques such as using an ice slurry to protect the kidney during laparoscopic partial nephrectomy. Additionally, Dr. Shalhav conducts clinical outcome studies focused on minimally invasive surgical options for urologic cancer. He has received awards from the Society of Laparoendoscopic Surgeons and the Endourological Society for his clinical work, research, and teaching.
Research topics
- Medicine
- Internal medicine
- Urology
- Oncology
- Surgery
- Radiology
Selected publications
The Journal of Urology · 2026-04-27
articleThe Journal of Urology · 2026-04-27
articleThe Journal of Urology · 2026-04-27
articleThe Journal of Urology · 2025-12-08
articlePURPOSE: Hemostatic agents (HAs) are typically used during robotic-assisted laparoscopic partial nephrectomy (RALPN) to minimize perioperative bleeding. However, high-quality evidence supporting their effectiveness is limited. We aimed to determine whether HAs reduce perioperative blood loss in patients undergoing RALPN. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of patients undergoing RALPN. Patients were randomized to HA+, in which HAs were assigned, and HA-, no HA. The primary end point was mean change in hemoglobin from preoperative baseline to postoperative day 1. Secondary outcomes included major bleeding complications (blood transfusion, reoperation, and endovascular intervention), length of stay, and 30-day readmission. RESULTS: = .7, 95% CI for group difference: [-5.4%] to 9.8%), as 4 patients (4.5%) in the HA- group and 6 patients (6.7%) in the HA+ experienced major bleeding complications. CONCLUSIONS: Routine use of HAs during RALPN does not seem to lower the risk for bleeding after surgery, as measured by the change in hemoglobin levels or major bleeding complications.
Clinical and Translational Radiation Oncology · 2024 · 1 citations
- Medicine
- Radiology
- Oncology
Background and purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic RCC is unclear. Here, we report outcomes of primary SABR across a diverse cohort of localized, recurrent, and metastatic RCC patients treated at our institution. Materials and methods: RCC patients treated with SABR to lesions of the kidney or nephrectomy bed at our institution with at least 6 months of follow-up were included for analysis. Local control, overall survival, and freedom from distant failure were estimated using the Kaplan-Meier method. Estimated glomerular filtration rate (eGFR) was assessed at baseline and following SABR. Results: (IQR -3 to 9). One patient required dialysis following SABR. Conclusion: This analysis demonstrates excellent local control rates across patients with localized, recurrent, and metastatic RCC treated with SABR. Treatment was associated with minimal eGFR decline.
International Journal of Radiation Oncology*Biology*Physics · 2024-09-27
articleOpen accessDifficult decisions in surgery: an evidence-based approach · 2022-01-01
book-chapterSenior authorThe Journal of Urology · 2021
- Medicine
- Urology
- Oncology
You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy III (MP42)1 Sep 2021MP42-15 SURVIVAL OUTCOMES IN PATIENTS UNDERGOING PARTIAL COMPARED TO RADICAL NEPHRECTOMY FOR EARLY-STAGE RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES Mohammad Mahmoud, Sean Kern, Fouad Harkal, Hristos Kaimakliotis, Timothy Masterson, Clint Cary, Arieh Shalhav, and Ronald Boris Mohammad MahmoudMohammad Mahmoud More articles by this author , Sean KernSean Kern More articles by this author , Fouad HarkalFouad Harkal More articles by this author , Hristos KaimakliotisHristos Kaimakliotis More articles by this author , Timothy MastersonTimothy Masterson More articles by this author , Clint CaryClint Cary More articles by this author , Arieh ShalhavArieh Shalhav More articles by this author , and Ronald BorisRonald Boris More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002063.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Small percentage of tumors with renal cell carcinoma (RCC) displays sarcomatoid features (SF). Outcomes are stage dependent with lower survival compared to RCC tumors without SF. We sought to evaluate the survival outcomes of partial nephrectomy (PN) compared to radical nephrectomy (RN) for early T1 N0 M0 renal cell carcinomas with SF. METHODS: The National Cancer Database from 2004 to 2014 was quired for T1a or T1b RCC with SF who underwent PN or RN. The Kaplan-Meier method and Log-rank test evaluated the impact of surgical approach, histology, and grade on overall survival (OS). RESULTS: Overall, 369 patients with three predominant histological subtypes met our inclusion criteria: Sarcomatoid RCC (SRCC) (125 patients, 36% had PN), clear cell RCC (CCRCC) with SF (182 patients, 35.7 % had PN), and RCC none-otherwise specified (NOSRCC) with SF (62 patients, 37.1% had PN). The OS was higher after PN over RN (60.47 vs 56.57 months, p=0.03, Figure 1). Positive margins (+m) were seen in 13 patients (3.52%) of which 12 occurred after PN (92.31%). Higher grade was associated with worse OS in SRCC (HR=3.65, p=0.003) and in CCRCC with SF (HR=2.51, p=0.004). In multivariate analysis, there were no statistically significant OS differences between PN and RN within each index histology. CONCLUSIONS: Partial nephrectomy is an acceptable option for Stage I RCC with sarcomatoid features despite higher rates of positive margins compared to radical nephrectomy. Because of the inherent invasiveness of sarcomatoid histology, higher grade translates to worse survival outcomes. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e777-e778 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mohammad Mahmoud More articles by this author Sean Kern More articles by this author Fouad Harkal More articles by this author Hristos Kaimakliotis More articles by this author Timothy Masterson More articles by this author Clint Cary More articles by this author Arieh Shalhav More articles by this author Ronald Boris More articles by this author Expand All Advertisement PDF DownloadLoading ...
Investigative and Clinical Urology · 2021 · 10 citations
Senior authorCorresponding- Medicine
- Urology
- Surgery
PURPOSE: Partial nephrectomy is associated with a 1%-2% risk of renal iatrogenic vascular lesion (IVL) that are commonly treated with selective angioembolization (SAE). The theoretical advantage of SAE is preservation of renal parenchyma by targeting only the bleeding portion of the kidney. Our study aims to assess the long-term effect of SAE on renal function, especially that this intervention requires potentially nephrotoxic contrast load injection. MATERIALS AND METHODS: A retrospective review of patients undergoing partial nephrectomy between 2002 and 2018 was performed, and patients who developed IVL were identified. A 1:4 matched case-control analysis was performed. Paired t-test and χ² test were used for continuous and categorical variables, respectively. Multivariable logistic and Cox proportional hazards regression analyses were used to identify risk factors and confounders for SAE and postoperative renal function. RESULTS: Eighteen patients found to have an IVL after partial nephrectomy were matched with 72 control patients. IVL's were more common in patients after minimally invasive partial nephrectomy (89% vs. 70%, p=0.008) and in those with higher RENAL nephrometry scores (8.8±2.0 vs. 6.5±1.8, p<0.001). On multivariable analysis, lower RENAL scores proved to decrease the odds of requiring postoperative SAE. No significant difference in renal function outcomes was seen at 24 months of follow-up after surgery. CONCLUSIONS: SAE for the management of IVL following partial nephrectomy is a safe and efficient procedure with no significant impact on short or long-term renal function. Less complex renal tumors with lower RENAL scores are less likely to require postoperative SAE.
Diagnosis of non-neoplastic renal diseases in renal mass biopsies
Journal of Onco-Nephrology · 2019-02-01 · 4 citations
articleOpen accessPurpose: As up to 25% of renal neoplasms may be benign, renal function preservation is often a priority in the management of small renal masses. Studies have demonstrated the occurrence of non-neoplastic renal diseases in nephrectomy specimens, but this has not been studied in the setting of renal mass biopsy. Therefore, we conducted this study to determine the feasibility of evaluating the non-neoplastic renal parenchyma in such a limited tissue sample. Methods: We identified 117 needle biopsies for renal lesions in adults from the Department of Pathology archives (2007–2017). Additional stains for periodic acid–Schiff or Jones methenamine silver were obtained as needed. Results: Of 117 cases, non-neoplastic renal parenchyma was absent in 91 cases (78%) and present in 26 cases (22%). Review of the hematoxylin and eosin slides identified 6 cases (5%) with significant diffuse and/or nodular mesangial sclerosis. Additional review of the periodic acid–Schiff and Jones’ stains demonstrated two cases that showed diffuse and focally nodular mesangial sclerosis that was consistent with diabetic nephropathy. Conclusions: The needle biopsy is increasingly useful in guiding the management of patients with small renal masses. Although less than 25% of renal mass biopsies had sufficient non-neoplastic renal parenchyma for pathologic evaluation, medical renal diseases, such as diabetic nephropathy, could be diagnosed. On the contrary, the biopsy specimens for urothelial lesions rarely yield sufficient adjacent non-neoplastic renal parenchyma for pathologic evaluation.
Frequent coauthors
- 229 shared
James E. Lingeman
Indiana University School of Medicine
- 213 shared
Tibério M. Siqueira
Universidade de Pernambuco
- 211 shared
Ryan F. Paterson
- 163 shared
Thomas A. Gardner
Indiana University School of Medicine
- 158 shared
Ralph V. Clayman
- 134 shared
Kevin C. Zorn
- 128 shared
Gregory P. Zagaja
University of Chicago
- 126 shared
Larry H. Stevens
Indiana University – Purdue University Indianapolis
Labs
Education
M.D.
University of Chicago
Awards & honors
- Awards from the Society of Laparoendoscopic Surgeons
- Awards from the Endourological Society
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Arieh Shalhav
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup